Nanotechnology could help fight diabetes
Injectable nanoparticles developed at Massachusetts Institute of Technology (MIT) may someday eliminate the need for patients with Type 1 diabetes to constantly monitor their blood-sugar levels and inject themselves with insulin. The nanoparticles weAstraZeneca issues update on accelerated oncology
AstraZeneca today announced that it will be moving three of its cancer compounds forward to Phase III
Aspirion Pharma is committed to ensuring that we always provide a service which is defined by process but which is driven by market realities. The sections on our service streams give a clear indication of our capabilities. However, it must be remembered that our aim is to provide a bespoke solution which maximises the "value-add" to our clients - hence our operational model is designed to heighten flexibility.
This allows Aspirion Pharma to create hybrid and innovative solutions which take into account individual client requirements and uncertain commercial situations.
